|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for HNRNPD |
 Gene summary |
| Basic gene Info. | Gene symbol | HNRNPD |
| Gene name | heterogeneous nuclear ribonucleoprotein D (AU-rich element RNA binding protein 1, 37kDa) | |
| Synonyms | AUF1|AUF1A|HNRPD|P37|hnRNPD0 | |
| Cytomap | UCSC genome browser: 4q21 | |
| Type of gene | protein-coding | |
| RefGenes | NM_001003810.1, NM_002138.3,NM_031369.2,NM_031370.2, | |
| Description | ARE-binding protein AUFI, type Aheterogeneous nuclear ribonucleoprotein D0hnRNP D0 | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 601324 | |
| HGNC : HGNC | ||
| HPRD : 03206 | ||
| Protein | UniProt: Q14103 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_HNRNPD | |
| BioGPS: 3184 | ||
| Pathway | NCI Pathway Interaction Database: HNRNPD | |
| KEGG: HNRNPD | ||
| REACTOME: HNRNPD | ||
| Pathway Commons: HNRNPD | ||
| Context | iHOP: HNRNPD | |
| ligand binding site mutation search in PubMed: HNRNPD | ||
| UCL Cancer Institute: HNRNPD | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID |
| Top |
| Ligand binding site mutations for HNRNPD |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | Y244 | H245R | COAD | 1 | G188 | L189I | COAD | 1 | A257 | M258V | STAD | 1 | Y244 | K242N | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for HNRNPD |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | A257 | M258V | -1.105202 | Y244 | K242N | -0.98544087 | G188 | L189I | -0.97046811 | Y244 | H245R | -0.78744189 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for HNRNPD from PDB |
| Top |
| Differential gene expression and gene-gene network for HNRNPD |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for HNRNPD |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for HNRNPD |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of HNRNPD go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | NUC | Nucleic Acids | 1wtb | A | G188 A257 | NUC | Nucleic Acids | 1x0f | A | G188 Y244 |
| Top |
| Conservation information for LBS of HNRNPD |
| Multiple alignments for Q14103 in multiple species |
| LBS | AA sequence | # species | Species | A257 | CEIKVAMSKEQ | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | E212 | EVESIELPMDN | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | E253 | GLSKCEIKVAM | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | F185 | PVKKIFVGGLS | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | F225 | NKRRGFCFITF | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | F227 | RRGFCFITFKE | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | G187 | KKIFVGGLSPD | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | G188 | KIFVGGLSPDT | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K183 | KEPVKKIFVGG | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K218 | LPMDNKTNKRR | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K221 | DNKTNKRRGFC | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | K255 | SKCEIKVAMSK | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | M1 | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | M215 | SIELPMDNKTN | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | P214 | ESIELPMDNKT | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | R222 | NKTNKRRGFCF | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | R223 | KTNKRRGFCFI | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | S2 | 3 | Homo sapiens, Rattus norvegicus, Mus musculus | Y244 | IMEKKYHNVGL | 3 | Homo sapiens, Rattus norvegicus, Mus musculus |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |